QuLab Medical Receives Award from JDRF to Advance Development of Minimally Invasive Dual Continual Glucose and Ketone Monitoring Patch for T1D

Herzliya, Israel and New York, N.Y., June 14, 2023 QuLab Medical (QuLab), a medical device and digital health startup, is pleased to announce a collaboration with JDRF, the leading global type 1 diabetes (T1D) research and advocacy organization, to advance monitoring technology for those with T1D. The award supports QuLab’s focus on developing a multi-metabolite wearable sensor for T1D management. In addition to providing funding, JDRF is also contributing strategic support through its deep expertise and vast network in the T1D field. 

QuLab’s goal is to develop a minimally invasive patch for continuous intradermal monitoring of glucose, ketone bodies and lactate, among other key metabolites. The study will integrate a unique electrochemical array system approach for detecting β-HB into QuLab’s patented field-effect-transistor (FET) sensor. The patch will provide simultaneous continuous monitoring of glucose and ketone bodies (CGKM) and send the data to a mobile device. People with T1D would create personalized metabolic profiles, and the wearable sensor would provide information for daily health and diabetes management, including avoiding diabetic ketoacidosis (DKA). 

“DKA remains a critical risk for people with type one diabetes, and continuous ketone monitoring can help prevent this dangerous acute complication by letting people know when their ketones are rising so they can take preventive action,” said Jonathan Rosen, PhD, director of research at JDRF. “Additionally, QuLab’s monitoring patch has the potential to enable safe use of SGLT inhibitors, a drug class with the potential to prevent heart and kidney complications in T1D that unfortunately comes with an increased risk of DKA.” 

About QuLab Medical 

QuLab Medical is a medical device and a digital health startup, focused on revolutionizing diabetes management, early diagnosis, and prevention, by offering a complete metabolic monitoring solution, based on users’ individual needs. Founded in 2016 at Tel Aviv University, QuLab Medical realized that Continuous Glucose Monitors (CGM) portray only part of the metabolism that underlies effective diabetes management, early diagnosis and possibly prevention. The newly developed patch is not only minimally invasive, i.e., as small, and inconspicuous as possible, but will also provide continuous monitoring of additional metabolic biomarkers. This will help the diabetic patient create their personalized metabolic profile and make better dietary and lifestyle decisions based on it. 

About JDRF  

JDRF’s mission is to accelerate life-changing breakthroughs to cure, prevent and treat T1D and its complications. To accomplish this, JDRF has invested more than $2.5 billion in research funding since our inception. We are an organization built on a grassroots model of people connecting in their local communities, collaborating regionally and globally for efficiency and broader fundraising impact, and uniting on a global stage to pool resources, passion, and energy. We collaborate with academic institutions, policymakers, and corporate and industry partners to develop and deliver a pipeline of innovative therapies to people living with T1D. Our staff and volunteers throughout the United States and our five international affiliates are dedicated to advocacy, community engagement, and our vision of a world without T1D. For more information, please visit jdrf.org or follow us on Twitter (@JDRF), Facebook (@myjdrf), and Instagram (@jdrfhq).  

About Type 1 Diabetes (T1D) 

T1D is an autoimmune condition that causes the pancreas to make very little insulin or none at all. This leads to dependence on insulin therapy and the risk of short or long-term complications, which can include highs and lows in blood sugar; damage to the kidneys, eyes, nerves, and heart; and even death if left untreated. Globally, it impacts nearly 9 million people. Many believe T1D is only diagnosed in childhood and adolescence, but diagnosis in adulthood is common and accounts for nearly 50% of all T1D diagnoses. The onset of T1D has nothing to do with diet or lifestyle. While its causes are not yet entirely understood, scientists believe that both genetic factors and environmental triggers are involved. There is currently no cure for T1D.